MEN1 and pituitary tumor: Regarding pituitary tumours, our patients showed a higher prevalence of PRLoma (over 41%) with respect to data reported in the MEN1 International guideline (20%) [1], in the DMSG database (16%) [8] and in the GTE cohort (30%) [10].